Personalized vaccine plus immunotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have triple-negative breast cancer (TNBC) that has not spread or is advanced/metastatic.
- You need to have a tumor sample that weighs at least 1 gram (about the size of a pea) to make the personalized vaccine.
- You cannot have serious health issues like uncontrolled heart disease, active infection, or autoimmune disease that needed treatment in the last 2 years.
- You must not be pregnant or breastfeeding, and if you can have children, you must agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This trial tests a vaccine called STEMVAC to see if it can help people with triple-negative breast cancer who still have moderate or large amounts of cancer after chemotherapy. The vaccine is designed to help the immune system fight any remaining cancer cells and improve survival.
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.